Literature DB >> 19491914

Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challenges.

Nidhi Jain1, Robert S Weinstein.   

Abstract

BACKGROUND: A 55-year-old woman with a 5-year history of osteoporosis treated for 4 years with an oral aminobisphosphonate presented with a recent vertebral fracture. A bone biopsy specimen revealed giant osteoclasts with more than 40 nuclear profiles. INVESTIGATIONS: Bone mineral density determinations, measurement of serum 25-hydroxyvitamin D, intact parathyroid hormone, calcium, inorganic phosphorus, alkaline phosphatase and creatinine levels, urinary excretion levels of the N-telopeptide of type 1 collagen, and bone biopsy. Examination of the patient and review of the bone specimen. DIAGNOSIS: Giant osteoclasts after long-term bisphosphonate use, without evidence of malignancy. MANAGEMENT: Interpretation of the bone biopsy specimen listed several bone disorders. The bone specimen was reviewed and the histological differential diagnosis was carefully considered. The giant osteoclasts were detached from bone and frequently apoptotic in a normal marrow stroma, with low-to-normal amounts of osteoid and osteoblasts. These features are typical of giant osteoclast formation after long-term aminobisphosphonate therapy. the patient was reassured that the bone findings were unlikely to be detrimental. Aminobisphosphonate treatment was reinstituted, and 1 year later the patient was asymptomatic.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19491914      PMCID: PMC2860596          DOI: 10.1038/nrrheum.2009.87

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  11 in total

1.  Bisphosphonate-induced osteopetrosis.

Authors:  Michael P Whyte; Deborah Wenkert; Karen L Clements; William H McAlister; Steven Mumm
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

2.  The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta.

Authors:  Frank Rauch; Rose Travers; Horacio Plotkin; Francis H Glorieux
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

3.  Alendronate for the treatment of osteoporosis in men.

Authors:  E Orwoll; M Ettinger; S Weiss; P Miller; D Kendler; J Graham; S Adami; K Weber; R Lorenc; P Pietschmann; K Vandormael; A Lombardi
Journal:  N Engl J Med       Date:  2000-08-31       Impact factor: 91.245

4.  Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group.

Authors:  M McClung; B Clemmesen; A Daifotis; N L Gilchrist; J Eisman; R S Weinstein; C Reda; A J Yates; P Ravn
Journal:  Ann Intern Med       Date:  1998-02-15       Impact factor: 25.391

Review 5.  Cellular and molecular mechanisms of action of bisphosphonates.

Authors:  M J Rogers; S Gordon; H L Benford; F P Coxon; S P Luckman; J Monkkonen; J C Frith
Journal:  Cancer       Date:  2000-06-15       Impact factor: 6.860

6.  Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.

Authors:  H G Bone; R W Downs; J R Tucci; S T Harris; R S Weinstein; A A Licata; M R McClung; D B Kimmel; B J Gertz; E Hale; W J Polvino
Journal:  J Clin Endocrinol Metab       Date:  1997-01       Impact factor: 5.958

Review 7.  Bisphosphonates: mode of action and pharmacology.

Authors:  R Graham G Russell
Journal:  Pediatrics       Date:  2007-03       Impact factor: 7.124

8.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

9.  Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Authors:  K G Saag; R Emkey; T J Schnitzer; J P Brown; F Hawkins; S Goemaere; G Thamsborg; U A Liberman; P D Delmas; M P Malice; M Czachur; A G Daifotis
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

10.  Giant osteoclast formation and long-term oral bisphosphonate therapy.

Authors:  Robert S Weinstein; Paula K Roberson; Stavros C Manolagas
Journal:  N Engl J Med       Date:  2009-01-01       Impact factor: 91.245

View more
  12 in total

Review 1.  Osteochemonecrosis: an overview.

Authors:  John Hellstein
Journal:  Head Neck Pathol       Date:  2014-11-20

2.  Muscle paralysis induces bone marrow inflammation and predisposition to formation of giant osteoclasts.

Authors:  Brandon J Ausk; Leah E Worton; Kate S Smigiel; Ronald Y Kwon; Steven D Bain; Sundar Srinivasan; Edith M Gardiner; Ted S Gross
Journal:  Am J Physiol Cell Physiol       Date:  2017-08-30       Impact factor: 4.249

3.  Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma.

Authors:  M Hiasa; J Teramachi; A Oda; R Amachi; T Harada; S Nakamura; H Miki; S Fujii; K Kagawa; K Watanabe; I Endo; Y Kuroda; T Yoneda; D Tsuji; M Nakao; E Tanaka; K Hamada; S Sano; K Itoh; T Matsumoto; M Abe
Journal:  Leukemia       Date:  2014-05-02       Impact factor: 11.528

4.  Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.

Authors:  Yu-Tzu Tai; Betty Y Chang; Sun-Young Kong; Mariateresa Fulciniti; Guang Yang; Yolanda Calle; Yiguo Hu; Jianhong Lin; Jian-Jun Zhao; Antonia Cagnetta; Michele Cea; Michael A Sellitto; Mike Y Zhong; Qiuju Wang; Chirag Acharya; Daniel R Carrasco; Joseph J Buggy; Laurence Elias; Steven P Treon; William Matsui; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2012-06-11       Impact factor: 22.113

5.  Denosumab-associated osteonecrosis of the jaw affects osteoclast formation and differentiation: Pathological features of two cases.

Authors:  Yuki Matsushita; Saki Hayashida; Kota Morishita; Hiroshi Sakamoto; Tomofumi Naruse; Yuki Sakamoto; Shin-Ichi Yamada; Souichi Yanamoto; Shuichi Fujita; Tohru Ikeda; Masahiro Umeda
Journal:  Mol Clin Oncol       Date:  2015-12-07

6.  Glucagon-like peptide 2 decreases osteoclasts by stimulating apoptosis dependent on nitric oxide synthase.

Authors:  Yi Lu; Dongdong Lu; Yu Hu
Journal:  Cell Prolif       Date:  2018-02-19       Impact factor: 6.831

7.  Giant osteoclasts in patients under bisphosphonates.

Authors:  Fabrice Mac-Way; Andrea Trombetti; Christian Noel; Marie-Hélène Lafage-Proust
Journal:  BMC Clin Pathol       Date:  2014-07-08

Review 8.  Bisphosphonate therapy in pediatric patients.

Authors:  Guiti Eghbali-Fatourechi
Journal:  J Diabetes Metab Disord       Date:  2014-12-17

9.  Zoledronic Acid Deteriorates Soft and Hard Tissue Healing of Murine Tooth Extraction Sockets in a Dose-Dependent Manner.

Authors:  Ryohei Kozutsumi; Shinichiro Kuroshima; Haruka Kaneko; Muneteru Sasaki; Akira Ishisaki; Takashi Sawase
Journal:  Calcif Tissue Int       Date:  2021-08-07       Impact factor: 4.333

10.  Mouse anti-RANKL antibody delays oral wound healing and increases TRAP-positive mononuclear cells in bone marrow.

Authors:  Shinichiro Kuroshima; Zeina Al-Salihi; Junro Yamashita
Journal:  Clin Oral Investig       Date:  2015-08-09       Impact factor: 3.573

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.